Takeda’s $330 Million Acquisition of PvP Biologics


Wilson Sonsini Goodrich & Rosati represented PvP Biologics in the acquisition.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced that it has acquired PvP Biologics, Inc. following the conclusion of a Phase 1 proof-of-mechanism study of investigational medicine TAK-062 (Kuma062) for the treatment of uncontrolled celiac disease. Wilson Sonsini Goodrich & Rosati advised PvP Biologics in the transaction.

TAK-062 is a potential best-in-class, highly potent super glutenase—a protein that degrades ingested gluten—that was computationally engineered to treat celiac disease, a serious autoimmune disease where the ingestion of gluten leads to inflammation and damage in the small intestine. The Phase 1 study investigated TAK-062’s safety and tolerability in both healthy volunteers and people with celiac disease. The ability of TAK-062 to degrade ingested gluten was studied in healthy volunteers. Takeda plans to submit data from the Phase 1 study for presentation at an upcoming medical congress.

Under the terms of the agreement, Takeda exercised its option to acquire PvP Biologics for a pre-negotiated upfront payment as well as development and regulatory milestones totaling up to $330 million. Takeda and PvP Biologics previously entered into a development and option agreement, under which PvP Biologics was responsible for conducting research and development through the Phase 1 proof-of-mechanism study of TAK-062 in exchange for funding by Takeda related to a pre-defined development plan.

The Wilson Sonsini team was led by partner Jeff Guise (Picture) and included senior counsel Clark Lin, and associate Nate Leachman.

Involved fees earner: Jeff Guise – Wilson Sonsini Goodrich & Rosati; Nathaniel Leachman – Wilson Sonsini Goodrich & Rosati; Clark Lin – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: PvP Biologics;

Author: Ambrogio Visconti